OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma

被引:10
|
作者
Dong, Huan [1 ]
Wang, Qiang [1 ]
Zhang, Guosen [1 ]
Li, Ning [1 ]
Yang, Mengsi [1 ]
An, Yang [1 ]
Xie, Longxiang [1 ]
Li, Huimin [1 ]
Zhang, Lu [1 ]
Zhu, Wan [2 ]
Zhao, Shuchun [3 ]
Zhang, Haiyu [3 ]
Guo, Xiangqian [1 ]
机构
[1] Henan Univ, Dept Predict Med, Inst Biomed Informat,Sch Software,Sch Basic Med S, Cell Signal Transduct Lab,Bioinformat Ctr,Henan P, Kaifeng 475004, Peoples R China
[2] Stanford Univ, Dept Anesthesia, Sch Med, Stanford, CA 94305 USA
[3] Stanford Univ, Dept Pathol, Sch Med, Stanford, CA USA
来源
CANCER MEDICINE | 2020年 / 9卷 / 05期
基金
中国国家自然科学基金;
关键词
diffuse large B-cell lymphoma; OSdlbcl; prognostic biomarker; survival analysis; CHEMOTHERAPY PLUS RITUXIMAB; 2016; REVISION; CHOP; PROGNOSIS; POOR; BIOMARKER; REVEALS; PROTEIN; DLBCL; TOOL;
D O I
10.1002/cam4.2829
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and is a clinical, pathological, and molecular heterogeneous disease with highly variable clinical outcomes. Currently, valid prognostic biomarkers in DLBCL are still lacking. To optimize targeted therapy and improve the prognosis of DLBCL, the performance of proposed biomarkers needs to be evaluated in multiple cohorts, and new biomarkers need to be investigated in large datasets. Here, we developed a consensus Online Survival analysis web server for Diffuse Large B-Cell Lymphoma, abbreviated OSdlbcl, to assess the prognostic value of individual gene. To build OSdlbcl, we collected 1100 samples with gene expression profiles and clinical follow-up information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. In addition, DNA mutation data were also collected from the TCGA database. Overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), disease-free interval (DFI), and progression-free interval (PFI) are important endpoints to reflect the survival rate in OSdlbcl. Moreover, clinical features were integrated into OSdlbcl to allow data stratifications according to the user's special needs. By inputting an official gene symbol and selecting desired criteria, the survival analysis results can be graphically presented by the Kaplan-Meier (KM) plot with hazard ratio (HR) and log-rank p value. As a proof-of-concept demonstration, the prognostic value of 23 previously reported survival associated biomarkers, such as transcription factors FOXP1 and BCL2, was evaluated in OSdlbcl and found to be significantly associated with survival as reported (HR = 1.73, P < .01; HR = 1.47, P = .03, respectively). In conclusion, OSdlbcl is a new web server that integrates public gene expression, gene mutation data, and clinical follow-up information to provide prognosis evaluations for biomarker development for DLBCL. The OSdlbcl web server is available at .
引用
收藏
页码:1790 / 1797
页数:8
相关论文
共 50 条
  • [41] Survival and consolidative radiotherapy in patients living with HIV and treated for diffuse large B-cell lymphoma
    Casimiro, Lucas Coelho
    Mauro, Geovanne Pedro
    Mello Medici, Carolina Trindade
    Weltman, Eduardo
    REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2020, 25 (06) : 956 - 960
  • [42] Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells
    Stromberg, Thomas
    Feng, Xiaoying
    Delforoush, Maryam
    Berglund, Mattias
    Lin, Yingbo
    Axelson, Magnus
    Larsson, Olle
    Georgii-Hemming, Patrik
    Lennartsson, Johan
    Enblad, Gunilla
    MEDICAL ONCOLOGY, 2015, 32 (07)
  • [43] Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma
    Ulu, Bahar Uncu
    Yigenoglu, Tugce Nur
    Basci, Semih
    Bakirtas, Mehmet
    Sahin, Derya
    Darcin, Tahir
    Yaman, Samet
    Bozan, Ersin
    Secilmis, Sema
    Candir, Burcu Arslan
    Yildiz, Jale
    Iskender, Dicle
    Baysal, Nuran Ahu
    Cakar, Merih Kizil
    Dal, Mehmet Sinan
    Altuntas, Fevzi
    LEUKEMIA RESEARCH, 2021, 110
  • [44] Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact
    Devin, Julie
    Kassambara, Alboukadel
    Bruyer, Angelique
    Moreaux, Jerome
    Bret, Caroline
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)
  • [45] Site-Specific Survival of Extra Nodal Diffuse Large B-Cell Lymphoma and Comparison With Gastrointestinal Diffuse Large B-Cell Lymphoma
    Gupta, Varsha
    Singh, Vinit
    Bajwa, Ravneet
    Meghal, Trishala
    Sen, Shuvendu
    Greenberg, David
    Anne, Madhurima
    Levitt, Michael J.
    JOURNAL OF HEMATOLOGY, 2022, 11 (02) : 45 - 54
  • [46] Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells
    Thomas Strömberg
    Xiaoying Feng
    Maryam Delforoush
    Mattias Berglund
    Yingbo Lin
    Magnus Axelson
    Olle Larsson
    Patrik Georgii-Hemming
    Johan Lennartsson
    Gunilla Enblad
    Medical Oncology, 2015, 32
  • [47] Diffuse large B-cell lymphoma: An institutional analysis
    Gogia, Ajay
    Das, Chandan K.
    Kumar, Lalit
    Sharma, Atul
    Tiwari, Akash
    Sharma, M. C.
    Mallick, Soumya
    SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (03) : 200 - 202
  • [48] Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles
    Cillessen, Saskia A. G. M.
    Meijer, Chris J. L. M.
    Notoya, Michitaka
    Ossenkoppele, Gert J.
    Oudejans, Joost J.
    JOURNAL OF PATHOLOGY, 2010, 220 (05) : 509 - 520
  • [49] Primary diffuse large B-cell lymphoma of orbit: A population-based analysis
    Chen, Yu-Qing
    Yue, Zi-Fan
    Chen, Sai-Nan
    Tong, Fei
    Yang, Wei-Hua
    Wei, Rui-Li
    FRONTIERS IN MEDICINE, 2022, 9
  • [50] Diffuse large B-cell lymphoma with MYC gene rearrangements Current perspective on treatment of diffuse large B-cell lymphoma with MYC gene rearrangements; case series and review of the literature
    de Jonge, A. V.
    Roosma, T. J. A.
    Houtenbos, I.
    Vasmel, W. L. E.
    van de Hem, K.
    de Boer, J. P.
    van Maanen, T.
    Lindauer-van der Werf, G.
    Beeker, A.
    Timmers, G. J.
    Schaar, C. G.
    Soesan, M.
    Poddighe, P. J.
    de Jong, D.
    Chamuleau, M. E. D.
    EUROPEAN JOURNAL OF CANCER, 2016, 55 : 140 - 146